CARM - Carisma Therapeutics Inc.
0.176
-0.017 -9.659%
Share volume: 186,206
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations:
0.05%
PREVIOUS CLOSE
CHG
CHG%
$0.19
-0.02
-0.09%
Fundamental analysis
8%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
20%
Performance
5 Days
-8.14%
1 Month
-56.00%
3 Months
-58.76%
6 Months
-58.76%
1 Year
-58.76%
2 Year
-58.76%
Key data
Stock price
$0.18
DAY RANGE
$0.18 - $0.21
52 WEEK RANGE
$0.16 - $0.49
52 WEEK CHANGE
-$58.76
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
Company detail
CEO: Thomas R. Cannell
Region: US
Website: sesenbio.com
Employees: 20
IPO year: 2014
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: sesenbio.com
Employees: 20
IPO year: 2014
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Carisma Therapeutics Inc. a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) Its lead product candidates include Vicineum, which is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer. The company was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Recent news
